Shelonitda Rose

2.7k total citations · 1 hit paper
56 papers, 1.8k citations indexed

About

Shelonitda Rose is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Shelonitda Rose has authored 56 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Hematology, 34 papers in Genetics and 15 papers in Oncology. Recurrent topics in Shelonitda Rose's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (28 papers), Acute Myeloid Leukemia Research (19 papers) and Chronic Myeloid Leukemia Treatments (19 papers). Shelonitda Rose is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (28 papers), Acute Myeloid Leukemia Research (19 papers) and Chronic Myeloid Leukemia Treatments (19 papers). Shelonitda Rose collaborates with scholars based in United States, Italy and France. Shelonitda Rose's co-authors include Margaret A. Shipp, Craig H. Moskowitz, Pier Luigi Zinzani, Jean‐Marie Michot, Philippe Armand, Ellen Snyder, John Kuruvilla, Alejandro D. Ricart, Arun Balakumaran and Vincent Ribrag and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Shelonitda Rose

51 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

2016 477 citations Philippe Armand, Margaret A. Shipp et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shelonitda Rose United States	16	1.1k	750	433	412	405	56	1.8k
Mirosław Majewski Poland	16	456 0.4×	522 0.7×	353 0.8×	279 0.7×	308 0.8×	28	1.4k
Linda Wellik United States	20	444 0.4×	724 1.0×	404 0.9×	306 0.7×	471 1.2×	34	1.3k
Ellen Schlette United States	28	700 0.7×	701 0.9×	1.3k 3.0×	1.3k 3.2×	412 1.0×	69	2.3k
Raja Luthra United States	24	526 0.5×	456 0.6×	367 0.8×	439 1.1×	607 1.5×	54	1.7k
Swen Weßendorf Germany	19	624 0.6×	521 0.7×	665 1.5×	387 0.9×	148 0.4×	31	1.6k
Darrin M. Beaupre United States	20	652 0.6×	502 0.7×	580 1.3×	424 1.0×	275 0.7×	49	1.4k
Enrico Tiacci Italy	27	703 0.7×	1.1k 1.5×	1.1k 2.4×	1.1k 2.6×	811 2.0×	77	2.8k
Anja Mottok Germany	28	1.2k 1.1×	477 0.6×	1.4k 3.3×	572 1.4×	188 0.5×	73	2.3k
Enrico Derenzini Italy	25	766 0.7×	405 0.5×	1.2k 2.8×	344 0.8×	145 0.4×	99	1.9k
Nathalie Gachard France	18	463 0.4×	311 0.4×	565 1.3×	354 0.9×	401 1.0×	57	1.3k

Countries citing papers authored by Shelonitda Rose

Since Specialization

Citations

This map shows the geographic impact of Shelonitda Rose's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shelonitda Rose with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shelonitda Rose more than expected).

Fields of papers citing papers by Shelonitda Rose

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shelonitda Rose. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shelonitda Rose. The network helps show where Shelonitda Rose may publish in the future.

Co-authorship network of co-authors of Shelonitda Rose

This figure shows the co-authorship network connecting the top 25 collaborators of Shelonitda Rose. A scholar is included among the top collaborators of Shelonitda Rose based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shelonitda Rose. Shelonitda Rose is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bhaskar, Atul, et al.. (2025). 3D Gait Analysis of Children Treated for Idiopathic Congenital Talipes Equinovarus After Completion of Ponseti Treatment. Indian Journal of Orthopaedics. 59(11). 1812–1822.

Bewersdorf, Jan Philipp, Rory M. Shallis, Ethan Thompson, et al.. (2025). Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab. Therapeutic Advances in Hematology. 16. 1584265104–1584265104.

Garcia‐Manero, Guillermo, Valeria Santini, Amer M. Zeidan, et al.. (2025). Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial. Advances in Therapy. 42(7). 3576–3589. 1 indexed citations

Harrison, Claire, Ruben A. Mesa, Moshe Talpaz, et al.. (2024). Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial. The Lancet Haematology. 11(10). e729–e740. 11 indexed citations

Zeidan, Amer M., Uwe Platzbecker, Matteo Giovanni Della Porta, et al.. (2024). Clinical benefit of luspatercept treatment (tx) in transfusion-dependent (TD), erythropoiesis-stimulating agent (ESA)–naive patients (pts) with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) in the COMMANDS trial.. Journal of Clinical Oncology. 42(16_suppl). 6565–6565. 2 indexed citations

Gerds, Aaron T., Claire Harrison, Jean‐Jacques Kiladjian, et al.. (2024). Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis. Blood Advances. 8(17). 4511–4522. 15 indexed citations

Garcia‐Manero, Guillermo, Matteo Della Porta, Valeria Santini, et al.. (2024). Changes in Red Blood Cell Transfusion Burden with Luspatercept Versus Epoetin Alfa in Patients with Lower-Risk Myelodysplastic Syndromes in the Phase 3, Open-Label, Randomized, Controlled COMMANDS Trial. Blood. 144(Supplement 1). 1832–1832. 1 indexed citations

Santini, Valeria, Rami S. Komrokji, Guillermo Garcia‐Manero, et al.. (2023). Long-Term Evaluation of Luspatercept in Erythropoiesis-Stimulating Agent (ESA)-Intolerant/Refractory Patients (pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Phase 3 MEDALIST Study. Blood. 142(Supplement 1). 915–915. 1 indexed citations

Harrison, Claire, Nicolaas Schaap, Alessandro M. Vannucchi, et al.. (2022). Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts. British Journal of Haematology. 198(2). 317–327. 24 indexed citations

10.

Zeidan, Amer M., Isaac W. Boss, C.L. Beach, et al.. (2021). A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML. Blood Advances. 6(7). 2219–2229. 64 indexed citations

11.

Platzbecker, Uwe, Valeria Santini, Rami S. Komrokji, et al.. (2021). Analysis of Duration of Response, Exposure-Adjusted Safety and Progression to Acute Myeloid Leukemia (AML) for Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Receiving Luspatercept in the MEDALIST Study. Blood. 138(Supplement 1). 1524–1524. 3 indexed citations

12.

Oza, Amit M., Maria Del Pilar Estevez-Diz, Eva‐Maria Grischke, et al.. (2020). A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53 -mutant Ovarian Cancer. Clinical Cancer Research. 26(18). 4767–4776. 89 indexed citations

13.

Harrison, Claire, Nicolaas Schaap, Alessandro M. Vannucchi, et al.. (2020). Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. American Journal of Hematology. 95(6). 594–603. 104 indexed citations

14.

Zeidan, Amer M., James D. Cavenagh, Maria Teresa Voso, et al.. (2019). Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Randomized Phase 2 Study. Blood. 134(Supplement_1). 829–829. 60 indexed citations

15.

Harrison, Claire, Nicolaas Schaap, Alessandro M. Vannucchi, et al.. (2019). Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, who were Either Ruxolitinib-Naïve or were Previously Treated with Ruxolitinib. Blood. 134(Supplement_1). 668–668. 13 indexed citations

16.

OGASAWARA, K., Kathryn J. Newhall, Stephen E. Maxwell, et al.. (2019). Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies. Clinical Pharmacokinetics. 59(2). 217–227. 24 indexed citations

17.

Ravandi, Farhad, Ivana Gojo, Mrinal M. Patnaik, et al.. (2016). A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML). Leukemia Research. 48. 92–100. 48 indexed citations

18.

Armand, Philippe, Margaret A. Shipp, Vincent Ribrag, et al.. (2016). Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. Journal of Clinical Oncology. 34(31). 3733–3739. 477 indexed citations breakdown →

19.

Oza, Amit M., Johanne I. Weberpals, Diane Provencher, et al.. (2015). An international, biomarker-directed, randomized, phase II trial of AZD1775 plus paclitaxel and carboplatin (P/C) for the treatment of women with platinum-sensitive, TP53-mutant ovarian cancer.. Journal of Clinical Oncology. 33(15_suppl). 5506–5506. 31 indexed citations

20.

Wagner, Andrew J., Udai Banerji, Amit Mahipal, et al.. (2015). A phase I trial of the human double minute 2 (HDM2) inhibitor MK-8242 in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 33(15_suppl). 10564–10564. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact